Shanghai Haohai Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 26, 2021 at 06:37 am EDT
Share
Shanghai Haohai Biological Technology Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 851.228 million compared to CNY 495.964 million a year ago. Operating income was CNY 274.537 million compared to CNY 11.389 million a year ago. Net income was CNY 231.022 million compared to CNY 27.527 million a year ago. Basic earnings per share from continuing operations was CNY 1.31 compared to CNY 0.15 a year ago.
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
SHANGHAI HAOHAI BIOLOGICAL TECHNOLOGY CO., LTD. 
